3 completed, 1 enrolling by invitation, 1 not yet recruiting, 1 recruiting. 2 Phase 3, 2 Phase 4, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 4 | 2 | Completed 2 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
Follow Cannabinoid Hyperemesis Syndrome: new trials by email Literature Review of Cannabinoid Hyperemesis Syndrome trials Research Report on Cannabinoid Hyperemesis Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department Haloperidol - Cannabinoid Hyperemesis Syndrome | Early Phase 1 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-11-01 | 2026-09-01 |
| Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department Olanzapine 10 milligram, Haloperidol - Cannabinoid Hyperemesis Syndrome | Phase 3 | Completed | Mercy Bon Secours Saint Vincent Medical Center | 31 | 2025-11-06 | 2026-10-14 |
| Cannabinoid Hyperemesis Syndrome. Prospective Multicenter Study of Patients Admitted to Adult Emergency Departments in Maine-et-Loire. D000096704, Cannabinoid Hyperemesis Syndrome | Recruiting | University Hospital, Angers | 3000 | 2025-07-25 | 2025-08-28 | |
| Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls Gastric Alimetry System - Motility Disorder, Gastroparesis | Enrolling by invitation | University of Calgary | 400 | 2022-11-01 | 2026-10-15 | |
| Droperidol on Prevention of Cannabis Hyperemesis Syndrome Droperidol Injectable Product, Diphenhydramine - Cannabis Hyperemesis Syndrome | Phase 3 | Unknown | Mercy Health Ohio | 45 | 2021-12-02 | 2023-01-20 |
| Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome Capsaicin, Placebo - Cannabinoid Hyperemesis Syndrome | Phase 4 | Completed | University of Virginia | 20 | 2020-12-01 | 2024-10-18 |
| Treatment Strategies in CHS Haloperidol - Cannabis Hyperemesis Syndrome | Phase 4 | Completed | University of Calgary | 4 | 2020-10-13 | 2022-08-10 |
Abdominal Pain (1) · Chediak-Higashi Syndrome (1) · Familial cyclic vomiting syndrome (1) · Gastroparesis (1) · Marijuana Abuse (1) · Nausea (1) · Vomiting (1)
Chemically-Induced Disorders (7) · Mental Disorders (7) · Substance-Related Disorders (7) · Marijuana Abuse (6) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Albinism (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Eye Diseases (1) · Eye Diseases, Hereditary (1) · Gastrointestinal Diseases (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1)
Haloperidol (3) · Capsaicin (1) · Diphenhydramine (1) · Droperidol (1)
University of Calgary (2) · Mercy Bon Secours Saint Vincent Medical Center (1) · Mercy Health Ohio (1) · University Hospital, Angers (1) · University of Illinois at Chicago (1) · University of Virginia (1)
United States (4) · Canada (2) · France (1)
Angela Holian, PharmD (1) · Christopher N Andrews, MD MSc FRCPC (1) · Todd Bolotin, MD (1) · Wesley Eilbert, MD (1)